Role of Hepatitis C Infection in Acute Liver Injury/Acute Liver Failure in North America

Ashwin Rao1 · Jody A. Rule1 · Giuliana Cerro-Chiang2 · Richard T. Stravitz3 · Brendan M. McGuire4 · Goo Lee5 · Robert J. Fontana6 · William M. Lee1

Received: 22 November 2021 / Accepted: 18 April 2022 / Published online: 11 May 2022  
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract
Background While hepatitis A and B are well-known causes of acute liver failure (ALF), few well-documented cases of hepatitis C virus (HCV) infection (absent preexisting liver disease or other liver insults) have been described that result in ALF. We reviewed the Acute Liver Failure Study Group registry for evidence of HCV as a primary or contributing cause to ALF.

Methods From January 1998 to January 2017, 2,332 patients with ALF (INR ≥ 1.5, any degree of hepatic encephalopathy) and 667 with acute liver injury (ALI; INR ≥ 2.0, no hepatic encephalopathy) were enrolled. Anti-HCV testing was done routinely, with confirmatory RT-PCR testing for HCV RNA where necessary.

Results A total of 136 patients were anti-HCV-antibody positive, as follows: 56 HCV RNA negative, 65 HCV RNA positive, and 8 with no result nor sera available for testing. Only three subjects with ALI/ALF were determined to represent acute HCV infection. Case 1: 47-year-old female with morbid obesity (BMI 52.4) developed ALF and recovered, experiencing anti-HCV seroconversion. Case 2: 37-year-old female using cocaine presented with ALI and fully recovered. Case 3: 54-year-old female developed ALF requiring transplantation and was anti-HCV negative but viremic prior to transplant experiencing anti-HCV seroconversion thereafter. Among 1636 APAP overdose patients, the 52 with concomitant chronic HCV had higher 3-week mortality than the 1584 without HCV (31% vs 17%, p = 0.01).

Conclusions ALI/ALF solely related to acute hepatitis C infection is very rare. Chronic HCV infection, found in at least 65 (2.2%) of ALI/ALF patients studied, contributed to more severe outcomes in APAP ALI/ALF; ClinicalTrials.gov number, NCT000518440.

Trial Registration ClinicalTrials.gov number NCT000518440.

Keywords Viral hepatitis · Fulminant hepatic failure · Liver transplantation

Abbreviations

| Abbreviation | Meaning                          |
|--------------|---------------------------------|
| ALI          | Acute liver injury              |
| ALF          | Acute liver failure             |
| ALFSG        | Acute liver failure study group |
| APAP         | Acetaminophen                    |
| BMI          | Body mass index                  |
| DILI         | Drug: induced liver injury      |
| HAV          | Hepatitis A virus               |
| HBsAg        | Hepatitis B surface antigen      |
| HBV          | Hepatitis B virus               |
| HIPAA        | Health Insurance Portability and Accountability Act |
| HCV          | Hepatitis C virus               |
| INR          | International normalized ratio  |
| NAFLD        | Nonalcoholic fatty liver disease |
| NASH         | Nonalcoholic steatohepatitis    |

* William M. Lee  
william.lee@utsouthwestern.edu

1 Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern Medical Center at Dallas, 5959 Harry Hines Blvd. Ste. 420, Dallas, TX 75390-8887, USA  
2 Division of Pulmonary Critical Care, Cedars-Sinai Medical Center, Los Angeles, CA, USA  
3 Lee-Hume Transplant Center, Virginia Commonwealth University, Richmond, VA, USA  
4 Division of Gastroenterology, University of Alabama, Birmingham, AL, USA  
5 Division of Anatomic Pathology, University of Alabama, Birmingham, AL, USA  
6 Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, MI, USA  

Springer
Introduction

Acute liver failure (ALF) is most commonly defined as the development of coagulopathy (international normalized ratio (INR) ≥ 1.5) and encephalopathy in a patient with an acute hepatic illness of ≤ 26 weeks’ duration, without underlying chronic liver disease [1]. With approximately 2000 cases diagnosed each year in the USA, ALF is a relatively rare clinical entity [2]. The most common causes include drug-induced liver injury, viral hepatitis, autoimmune liver disease, and shock or hypoperfusion, though a small proportion of cases are ultimately considered as indeterminate [3, 4]. Etiologies also vary worldwide, with drug-induced etiologies (i.e., acetaminophen and idiosyncratic DILI) more common in Western countries while viral hepatitis (i.e., hepatitis A, B, and E) predominates in emerging countries [3–6]. All etiologies of ALF are characterized by varying severity of encephalopathy, coagulopathy, metabolic abnormalities, features of systemic inflammatory response syndrome, circulatory dysfunction, and multi-organ failure. Despite these clinical features, the etiology of ALF is important to delineate, as it determines specific treatments and provides one of the best indicators of prognosis [4, 7, 8]. While hepatitis A, B, and E are well-known causes, there have been few well-documented cases of acute hepatitis C virus (HCV) infection causing ALF absent preexisting liver disease or concomitant liver insults with prior literature limited to individual case reports [9–14]. Our aim was to review the Acute Liver Failure Study Group registry for any evidence of HCV as a primary or contributing cause of ALF and ALI.

Patients and Methods

The Acute Liver Failure Study Group (ALFSG) is a multi-center consortium of 23 sites, funded by the National Institute of Diabetes and Digestive and Kidney Diseases with an aim of elucidating the causes, clinical features, and outcomes of adult patients with ALF and Acute Liver injury (ALI). Between January 1998 and January 2017, 2332 adult patients meeting entry criteria for ALF and 667 adult patients meeting entry criteria for ALI were enrolled [4]. ALF was defined as coagulopathy (INR ≥ 1.5), any degree of hepatic encephalopathy, and an illness of ≤ 26 weeks’ duration in patients without known chronic liver disease [4]. ALI was defined as an INR ≥ 2, absence of hepatic encephalopathy, and an illness of ≤ 26 weeks’ duration in patients without known chronic liver disease [15]. Comprehensive demographic, clinical, and laboratory values were recorded prospectively at enrollment and serially for 7 days. Outcomes at 21 days post-enrollment were classified as transplant-free survival, liver transplantation, or death. A written informed consent was obtained from enrolled subjects if not encephalopathic or from legally authorized representative if impaired mentation was present. Each center’s Institutional Review Board approved the study, centers abided by the Health Insurance Portability and Accountability Act (HIPAA), and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki.

The primary etiology of ALF or ALI was determined initially by the site investigator. Different from hepatitis A and B where IgM antibodies are available, there is no readily available marker that defines acute hepatitis C [16]. Accordingly, a diagnosis of acute HCV infection required the presence of HCV RNA with absence of anti-HCV antibody (presumed diagnosis during the seronegative window period) or the presence of both HCV RNA and anti-HCV antibody with a recent prior negative HCV-antibody test (diagnosis based on anti-HCV seroconversion) [17–20]. Anti-HCV-antibody and reverse transcriptase polymerase chain reaction (RT-PCR) testing for HCV RNA was done at local sites. If RT-PCR had not been performed locally, available banked sera were tested at a central laboratory. Competing causes of ALF or ALI that were evaluated based on detailed history, extensive laboratory and serologic testing, hepatobiliary imaging, and liver biopsy (if indicated) included acute hepatitis A, B, or E and herpes family or occult/novel viruses, idiosyncratic drug-induced liver injury (DILI), acetaminophen-induced liver toxicity (APAP), shock/ischemic injury, autoimmune hepatitis, Wilson’s disease, pregnancy, Budd-Chiari syndrome, and infiltrating malignancy [4].

All cases were subsequently examined by a causality adjudication committee of 9 experienced hepatologists, with each case validated or revised after rigorous elimination of other etiologies. Additional laboratory testing (including, but not limited to, APAP-CYS protein adducts [21], HEV testing, viral sequences via microarray analysis, and metagenomics next-generation sequencing) were performed on sera when available and as indicated. Local sites were also asked to provide diagnostic biopsy and/or explant pathology results, which may not have been available for site investigators at enrollment.

Between-group differences of categorical variables were tested using the chi-square test and all statistical analyses were performed using IBM SPSS Statistics (version 26; SPSS Inc. Chicago, IL). A p value < 0.05 was considered statistically significant.
Results

Of the 2332 ALF and 667 ALI patients, 110 (4.72%) and 25 (3.75%), respectively, tested positive for anti-HCV antibody (Fig. 1). Five cases were subsequently determined to not meet criteria for ALF or ALI by adjudication; 56 of the 130 remaining patients (43.1%) tested negative for HCV RNA indicating either false positive or resolved HCV infection. Among the 56 patients with undetectable HCV RNA, an alternative etiology for ALF or ALI was determined in all; six underwent liver transplantation (10.7%) and 9 died (16.1%), yielding a transplant-free survival of 69.6% (39 of 56) (Table 1). Among 8 ALF patients who tested positive for HCV antibody where RT-PCR for HCV RNA could not be performed, alternate diagnoses were also identified: five were due to APAP overdose, one due to autoimmune hepatitis, one due to DILI, and one due to shock/ischemia.

There were 66 remaining patients with both detectable anti-HCV antibody and HCV RNA; 65 were determined to represent chronic HCV infection with an alternative etiology for ALF or ALI in each case (Table 1). Of note, based on adjudication with compatible medication and ingestion

Fig. 1 ALF and ALI cases stratified by HCV status; 56 patients were anti-HCV-antibody positive and HCV RNA negative consistent with prior resolved infection or false-positive test result; 66 patients were anti-HCV-antibody positive and HCV RNA positive, consistent with current HCV infection; 8 patients were anti-HCV-antibody positive, but HCV RNA testing could not be obtained

Springer
histories and serum APAP levels and/or APAP-CYS adduct testing, 52 of the 65 (80%) were deemed secondary to APAP overdose. Of these, 29/31 had toxic adduct levels and 31/40 tested has toxic APAP levels. Only three had not been tested for either marker of toxicity but had strong histories only. The remaining etiologies included shock/ischemia (5), idiosyncratic drug-induced liver injury (3), de novo acute hepatitis B virus (2), indeterminate (2), and malignancy (1). Acute hepatitis B virus cases were diagnosed based on the detection of hepatitis B surface antigen (HBsAg) and presence of immunoglobulin M antibody to hepatitis B core antigen. Two cases, one presenting 5 years post-transplantation for chronic HCV and the other with a known history of chronic HCV, remained indeterminate after undergoing extensive serologic testing. Liver biopsy in one was consistent with chronic hepatitis C plus possible DILI but no agent could be implicated. Among these 65 chronic anti-HCV-positive patients, one underwent liver transplantation (1.5%) and 21 died (32.4%), yielding a transplant-free survival of 61.5% (40 out of 65).

### Table 1

| Etiology of ALF or ALI in HCV-antibody-positive, HCV RNA-negative cases | Cases (n) | Etiology of ALF or ALI in HCV-antibody-positive, HCV RNA-positive cases | Cases (n) |
|---|---|---|---|
| Acetaminophen (APAP) | 34 | Acetaminophen (APAP) | 52 |
| Hepatitis B Virus | 5 | Shock/Ischemia | 5 |
| Shock/Ischemia | 4 | Idiosyncratic Drug-Induced Liver Injury | 3 |
| Idiosyncratic Drug-Induced Liver Injury | 4 | Hepatitis B Virus | 2 |
| Autoimmune Hepatitis | 5 | Indeterminate | 2 |
| Wilson’s Disease | 1 | Malignancy | 1 |
| Hepatitis A Virus | 1 | | |
| Indeterminate | 2 | | |

| Outcome | Cases (n, %) | Outcome | Cases (n, %) |
|---|---|---|---|
| Transplant-Free Survival | 39 (69.7%) | Transplant-Free Survival | 40 (61.5%) |
| Liver Transplantation | 6 (10.7%) | Liver Transplantation | 1 (1.5%) |
| Death | 9 (16%) | Death | 21 (32.4%) |
| Unknown | 2 (3.6%) | Unknown | 3 (4.6%) |

### Case Histories

Three remaining cases were attributed to acute hepatitis C, two of whom were anti-HCV negative and one antibody positive at initial testing. Details of each case are outlined below (Table 2).

**Case 1:** A 47-year-old African-American female with a history of morbid obesity (BMI 52.4 kg/m²) and diabetes mellitus presented with abdominal pain and was found to have elevated aminotransferases, coagulopathy, and Grade 2 encephalopathy consistent with ALF. Serologic and imaging workup ruled out other etiologies. Initially, anti-HCV antibodies were not detected, but re-testing during the hospital course revealed a positive HCV antibody and a HCV RNA viral load of 595,000 IU/mL, genotype not determined. A diagnosis of acute HCV infection, presumably acquired via sexual transmission with a known HCV-positive partner, was made. Though histological findings of confluent necrosis confirmed acute hepatitis, liver biopsy also revealed a background of nonalcoholic steatohepatitis (NASH). The patient recovered fully without requiring transplantation.

**Case 2:** A 37-year-old Caucasian female with a history of intravenous drug use presented with abdominal pain and jaundice. She demonstrated elevated aminotransferases and coagulopathy, but no encephalopathy. The patient was HCV-antibody and HCV RNA positive (with a recently reported negative antibody negative test); viral load 1,720,000 IU/mL, genotype not determined. She endorsed recent cocaine and opioid use prior to admission, with urine toxicology screens positive for both. The patient recovered without a transplant.

**Case 3:** A 54-year-old African-American female with a history of obesity (BMI 36 kg/m²) and prior gastric bypass surgery with flank pain and elevated aminotransferases and coagulopathy developed hepatic encephalopathy consistent with ALF. Serologic and imaging workup did not identify an etiology; HCV antibody was negative and HCV RNA testing was not obtained at the time. Initially presumed to
have indeterminate ALF, she received an orthotropic liver transplant and recovered. Explant histology showed panlobular hepatitis with regeneration and massive necrosis; no evidence of cirrhosis or fatty liver (Fig. 2). At approximately 10 months post-transplant, new aminotransferase elevations prompted hepatitis C antibody and RNA testing with positive results for both. Given these findings, stored serum obtained prior to transplantation was retrieved, demonstrating an HCV RNA viral load of 6,200,000 IU/mL (genotype 1a), confirming a highly likely diagnosis of acute hepatitis C. She had presumably acquired her infection via sexual transmission with a new partner known to be HCV positive.

![Fig. 2 Explanted Liver from Case 3 (H&E stain). A (low power) Lobules (short arrows) show a significant panlobular inflammatory infiltrate with lobular architectural disarray and prominent hepatocyte drop-out. A portal tract on the right (long arrows) reveals an inflammatory infiltrate with interface activity. No bile duct injury is seen. There is no evidence of cirrhosis. B (high power) The lobular inflammatory infiltrate (long arrows) consists predominantly of lymphocytes with plasma cells. Cholestasis (short arrow) is also noted.](image-url)
She was subsequently treated and achieved a sustained virologic response.

**Comparison of Acetaminophen Overdose Cases With and Without Detectable HCV RNA**

To determine whether hepatitis C coinfection might impact outcomes, we compared the 65 subjects found to have active chronic hepatitis C (anti-HCV, HCV RNA positive) with the anti-HCV-negative, HCV RNA-negative group. Since acetaminophen-induced ALI/ALF comprised 80% of the RNA-positive group, we only made the comparisons within this etiology. Those who were RNA positive demonstrated increased overall mortality when compared to the RNA-negative group, although rates of transplant-free survival and transplantation were not significantly different (Table 3).

**Discussion**

The present study demonstrates that while the finding of a positive HCV antibody and/or chronic hepatitis C is prevalent in patients with ALI/ALF with an overall incidence of 4.5%, acute hepatitis C is rarely if ever the sole cause of ALF or ALI. Only three of 2,999 consecutive cases of ALF or ALI were deemed related to acute HCV infection. All patients had at least one comorbid condition and only one required transplantation.

Case 1 experienced HCV-antibody seroconversion. Additionally, her high BMI and confirmed NAFLD on liver biopsy certainly contributed to her clinical course and outcome [22–24]. Case 2, who met criteria for ALI but not ALF, presented with possible acute HCV infection given her high aminotransferases, significant HCV viral load, and positive HCV-antibody test. Though she alleged that she had negative antibody testing months prior, no earlier HCV records were available. Her history of chronic intravenous drug use, recent cocaine use, and positive urine drug screens makes it difficult to exclude concomitant liver injury secondary to cocaine and/or chronic hepatitis C. Finally, Case 3 appeared to represent the best example of acute hepatitis C leading to ALF. She was diagnosed retrospectively having had a negative HCV antibody but positive HCV RNA on presentation with ALF. Despite a high likelihood for preexisting NAFLD, she did not have other features of metabolic syndrome and her explant did not show any features of NASH or cirrhosis; only massive lobular necrosis [25].

Previously described instances of acute HCV infection as a primary driver of ALF are limited to case reports. In one case, a patient with presumed transfusion-acquired acute HCV infection presented with high levels of viremia and jaundice, coagulopathy, and encephalopathy, consistent with HCV-precipitated ALF; however non-viral etiologies were not excluded [9]. A more recent report details an instance of acute HCV-mediated ALF requiring liver transplant, complicated by immediate recurrent biopsy-proven HCV-mediated hepatitis and subsequently managed with sofosbuvir and ribavirin [12]. While most cases of acute HCV infection are asymptomatic, it has been proposed that there might be specific virulent strains, such as the JFH-1 variant isolated from a patient with HCV-mediated ALF in Japan, that could result in fulminant hepatic failure [26]. However, subsequent in vivo analysis of the same strain showed only mild infection with low-level viremia and absence of laboratory or histological hepatitis.7

The limited published literature combined with the dearth of cases in the ALFSG registry suggests that HCV rarely causes acute hepatic synthetic dysfunction and encephalopathy severe enough to meet criteria for ALF. Only 10–15% of acute HCV infections demonstrate symptomatic hepatitis, accompanied by moderate aminotransferase elevations and mild hyperbilirubinemia without synthetic dysfunction [19, 28–30]. Both hepatitis A and B evoke vigorous immune responses in those who are not immunosuppressed, with the majority of patients demonstrating clinical acute hepatitis and clearing the virus readily [30, 31]. By contrast, HCV eludes host mediated immune clearance via neutralizing antibodies, modulating complement expression, and suppressing key mediators of interferon signaling [31–34]. The same mechanisms responsible for viral persistence of HCV may explain why it rarely causes ALF [35]. Thus, acute hepatitis C likely has a different mechanism of liver injury that makes ALF a rare event, in our series, a one in a thousand occurrence.

| Table 3 Effect of chronic HCV status on outcomes in acetaminophen-induced ALI/ALF. Chronic HCV infection was associated with increased overall mortality, though rates of transplantation and spontaneous survival did not differ. |
| --- |
| **Outcome** | Acetaminophen-induced ALI/ALF without Chronic HCV (n, %) | Acetaminophen-induced ALI/ALF with Chronic HCV (n, %) | **p value** |
| Transplant-Free Survival | 1072 (67.7%) | 32 (61.5%) | 0.22 |
| Liver Transplantation | 95 (6%) | 1 (1.9%) | 0.18 |
| Death | 272 (17.2%) | 16 (30.8%) | 0.01 |
| Unknown | 155 (9.8%) | 3 (5.8%) | 0.24 |
| Total | 1584 (100%) | 52 (100%) | |

© Springer
In reviewing ALF and ALI patients with preexisting chronic HCV, the most common primary etiology was APAP in 80% of the cases. Though acetaminophen is the most common cause in ALF and ALI in the USA (i.e., ~ 50% of cases likely related to APAP), its association with chronic HCV patients appears much higher than with other etiologies of ALF and ALI. Both chronic hepatitis C and APAP toxicity have been associated with high-risk behaviors [36, 37]. Future studies are needed to validate the increased representation of acetaminophen cases in our HCV-infected ALF population and delineate the role that impulsivity may play in developing each.

The presence of HCV infection in the APAP group was significantly associated with increased 3-week mortality compared to APAP patients without HCV or who were anti-HCV positive but RNA negative. We were unable to analyze the effects of chronic HCV on other etiologies of ALI/ALF due to small case numbers. Chronic HCV infection in APAP overdose hospitalizations has been associated in the past with risk of progression from ALI to ALF, as well as increased length of stay and overall mortality [38]. Patients with chronic HCV demonstrate higher oxidative stress, evidence by increased levels of superoxide dismutase and lipid peroxidation metabolites, ultimately leading to reduced glutathione stores [39–41]. Depleted glutathione stores may subsequently exacerbate the effects of APAP overdose by reducing the capacity to detoxify N-acetyl-p benzoquinoneimine (NAPQI) into non-toxic metabolites. Further prospective and mechanistic studies are needed to clarify if chronic HCV potentiates the hepatotoxicity in APAP overdose, as well as in other forms of ALI and ALF.

Our study is not without limitations. It is possible but unlikely that very early cases of acute HCV infection went undiagnosed, as data suggest HCV RNA becomes reliably detectable by 10–14 days after viral exposure and confirmatory HCV RNA testing was not done in every patient [20, 42]. Another limitation is the lack of a clinically available specific diagnostic test, for example IgM HCV antibodies, which might more definitively identify acute infection in difficult to adjudicate cases, such as case 2. Additionally, in 8 patients, HCV status was unable to be determined due to lack of available sera. However, each of the 65 cases deemed chronic HCV infection and 8 cases deemed indeterminate presented with definite alternative etiologies of ALI/ALF. Our study population limited to North American sites would not accurately capture cases that might have greater severity in other areas of the world. Further studies with robust evaluation to exclude competing causes in geographically distinct populations are needed to estimate the true worldwide incidence of HCV-mediated acute liver failure. Nonetheless, the large study population of the ALFSG over more than 20 years has afforded a robust survey vehicle, to help determine if hepatitis C can cause ALF. Finally, resources to perform viral quasispecies analysis and evolution over time were not available to test our 3 cases of presumed HCV-related ALI/ALF.

In summary, among 2999 patients enrolled in 23 North American sites over a 20-year period, at most only three acute hepatitis C ALF or ALI cases were identified. Our data also demonstrate that chronic HCV infection may lead to more severe outcomes when combined with other etiologies of ALI or ALF, primarily APAP hepatotoxicity. However, acute HCV as the sole etiology of ALF, in the absence of antecedent liver disease or coexisting liver insults, is rare, despite the resurgence of acute HCV infections in the USA.

Funding This work was supported by NIDDK (Grant No. U-01 58369).

Declarations

Conflict of interest WML serves as a consultant for AbbVie, Genentech, Firma, Karuna, SeaGen, Cortezyme, Pfizer, and Alnylam. He receives research funding to conduct clinical trials from Merck, BMS, Intercept, Novo Nordisk, Eiger, and Alexion. RJF receives research support from AbbVie, Gilead, and Bristol Myers Squibb and has consulted for Sanofi. RTS receives funding from IL and Exalenz. AR, JR, GC, BMM, and GL have no financial disclosures to report. All authors certify that they have no non-financial interests (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.

References

1. Polson J, Lee WM. American Association for the Study of Liver D. AASLD position paper: the management of acute liver failure. *Hepatology* 2005;41:1179–1197.
2. Bower WA, Johns M, Margolis HS et al. Population-based surveillance for acute liver failure. *Am J Gastroenterol* 2007;102:2459–2463.
3. Germani G, Theoscharidou E, Adam R et al. Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. *J Hepatol* 2012;57:288–296.
4. Ostapowicz G, Fontana RJ, Schiodt FV et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. *Ann Intern Med* 2002;137:947–954.
5. Acharya SK, Dasarathy S, Kumer TL et al. Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome. *Hepatology* 1996;23:1448–1455.
6. Acharya SK, Batra Y, Hazari S et al. Etiopathogenesis of acute hepatic failure: Eastern versus Western countries. *J Gastroenterol Hepatol* 2002;17:S268–S273.
7. Bernal W, Auzinger G, Dhawan A et al. Acute liver failure. *Lancet* 2010;376:190–201.
8. O’Grady JG, Alexander GJ, Hayllar KM et al. Early indicators of prognosis in fulminant hepatic failure. *Gastroenterology* 1989;97:439–445.
9. Farci P, Alter HJ, Shimoda A et al. Hepatitis C virus-associated fulminant hepatic failure. *N Engl J Med* 1996;335:631–634.
10. Kanazaki H, Takaki A, Yagi T et al. A case of fulminant liver failure associated with hepatitis C virus. *Clin J Gastroenterol* 2014;7:170–174.
11. Thiel AM, Rissland J, Lammert F et al. Acute liver failure as a rare case of a frequent disease. Z Gastroenterol 2018;56:255–258.

12. Tracy B, Shrestha R, Stein L, et al. Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure. Transpl Infect Dis 2017;19.

13. Younis BB, Arshad R, Khurshid S et al. Fulminant hepatic failure (FHF) due to acute hepatitis C. Pak J Med Sci 2015;31:1009–1011.

14. Yu ML, Hou NJ, Dai CY et al. Successful treatment of fulminant hepatitis C by therapy with alpha interferon and ribavirin. Anti-microb Agents Chemother 2005;49:3986–3987.

15. Koch DG, Speiser JL, Durkalski V et al. The natural history of severe acute liver injury. Am J Gastroenterol 2017;112:1389–1396.

16. Brillanti S, Masci C, Miglioli M et al. Serum IgM antibodies to hepatitis C virus in acute and chronic hepatitis C. Arch Virol Suppl 1993;8:213–218.

17. Ghany MG, Morgan TR. Panel A-IHCG. Hepatitis C guidance update 2019: American Association for the study of liver diseases-infectious diseases society of america recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology 2020;71:686–721.

18. Centers for Disease C. Prevention Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wky Rep 2013;62:362–365.

19. Cox AL, Netski DM, Mosbruger T et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis 2005;40:951–958.

20. Glynn SA, Wright DJ, Kleinman SH et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005;45:994–1002.

21. Khandelwal N, James LP, Sanders C, Larson AM, Lee WM. Acute Liver Failure Study Group. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology 2011;53:567–576.

22. Fan R, Wang J, Du J. Association between body mass index and fatty liver risk: a dose-response analysis. Sci Rep 2018;8:15273.

23. Loomis AK, Kabadi S, Preiss D et al. Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record prospective studies. J Clin Endocrinol Metab 2016;101:945–952.

24. Saída T, Fukushima W, Ohfuji S et al. Effect modification of body mass index and body fat percentage on fatty liver disease in a Japanese population. J Gastroenterol Hepatol 2014;29:128–136.

25. Morita S, Neto Dde S, Morita FH et al. Prevalence of non-alcoholic fatty liver disease and steatohepatitis risk factors in patients undergoing bariatric surgery. Obes Surg 2015;25:2335–2343.

26. Kato T, Furuakasaka A, Miyamoto M et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J Med Virol 2001;64:334–339.

27. Kato T, Choi Y, Elmowalid G et al. Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation. Hepatology 2008;48:732–740.

28. Loomba R, Rivera MM, McBurney R et al. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment Pharmacol Ther 2011;33:559–565.

29. Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet 2008;372:321–332.

30. Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80–88.

31. Horner SM. Activation and evasion of antiviral innate immunity by hepatitis C virus. J Mol Biol 2014;426:1198–1209.

32. Kim H, Meyer K, Di Bisceglie AM et al. Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function. J Virol 2013;87:5858–5867.

33. Mazumdar B, Kim H, Meyer K et al. Hepatitis C virus proteins inhibit C3 complement production. J Virol 2012;86:2221–2228.

34. Banerjee A, Mazumdar B, Meyer K et al. Transcriptional repression of C4 complement by hepatitis C virus proteins. J Virol 2011;85:4157–4166.

35. Kwon YC, Ray RB, Ray R. Hepatitis C virus infection: establishment of chronicity and liver disease progression. EXCLI J 2014;13:977–996.

36. Dantas-Duarte A, Morais-de-Jesus M, Nunes AP et al. Risk-taking behavior and impulsivity among HCV-infected patients. Psychiatry Res 2016;243:75–80. https://doi.org/10.1016/j.psychres.2016.04.114.

37. Pezzia C, Sanders C, Welch S, Bowling A, Lee WM. Acute Liver Failure Study Group. Psychosocial and behavioral factors in acetaminophen-related acute liver failure and liver injury. J Psychosom Res 2017;101:51–57. https://doi.org/10.1016/j.jpsychores.2017.08.006.

38. Nguyen GC, Sam J, Thuluvath PJ. Hepatitis C is a predictor of acute liver injury among hospitalizations for acetaminophen overdose in the United States: a nationwide analysis. Hepatology 2008;48:1336–1341. https://doi.org/10.1002/hep.22536.

39. Paradis V, Mathurin P, Kollinger M, Imbert-Bismut F, Charlotte F, Piton A et al. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J Clin Pathol 1997;50:401–406.

40. Larrea E, Beloqui O, Munoz-Navas MA, Civeira MP, Prieto J. Superoxide dismutase in patients with chronic hepatitis C virus infection. Free Radic Biol Med 1998;24:1235–1241.

41. Barbaro G, Di LG, Ribersani M, Soldini M, Giancaspro G, Bellomo G et al. Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype. J Hepatol 1999;30:774–782.

42. Busch MP, Murthy KK, Kleinman SH et al. Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes. Blood 2012;119:6326–6334.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.